International Clinical Trial: A Study of Atezolizumab Plus Pembrolizumab in Combination with Chemotherapy for First-Line Treatment of HNSCC

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119431) titled 'A Study of Atezolizumab Plus Pembrolizumab in Combination with Chemotherapy for First-Line Treatment of HNSCC' on Feb. 27.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The affiliated hospital of southwest medical university

Condition: Recurrent or metastatic squamous cell carcinoma of the head and neck that cannot be treated locally

Intervention: Trial Group:Atezolizumab 5mg/kg on day 1, every 3 weeks Cisplatin 75mg/m^2 (days 2+3) or Carboplatin AUC=5 (day 2), every 3 weeks Fluorouracil 750mg/m^2 (days 2-6), every 3 weeks

Recruitment Status: Not Recruiting

Phase: N/A

Dat...